Research progress on the role of epithelial-mesenchymal transition in breast cancer endocrine therapy resistance
10.12354/j.issn.1000-8179.2024.20240810
- VernacularTitle:上皮间质转化在乳腺癌内分泌治疗耐药中的作用研究进展
- Author:
Wang TONG
1
;
Wang YILIN
;
Cui QI
Author Information
1. 天津医科大学肿瘤医院乳腺肿瘤二科,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,乳腺癌防治教育部重点实验室,天津市"肿瘤防治"重点实验室(天津市 300060)
- Keywords:
breast cancer;
endocrine therapy;
tumor treatment resistance;
epithelial-mesenchymal transition(EMT)
- From:
Chinese Journal of Clinical Oncology
2024;51(18):968-972
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is one of the most common malignant tumors and the primary cause of cancer-related deaths in women globally.Approximately 70%of all breast cancers are hormone receptor-positive,and endocrine therapy is the main treatment for this cancer type.Endocrine therapy resistance often leads to treatment failure and the death of patients,which is a clinical problem that needs urgent solu-tion.Research in the past few decades has shown that epithelial-mesenchymal transition(EMT)is a key event in cancer metastasis and asso-ciated with tumor treatment resistance.Increasing evidence suggests that EMT plays a key role in endocrine therapy resistance in breast cancer.This article reviews latest research on the relationship between EMT and endocrine resistance in breast cancer and discusses the specific molecular mechanisms involved,to provide new ideas and potential therapeutic targets for reversing endocrine therapy resistance in breast cancer.
